Recently there has been renewed interest in strategies aimed at generating active antitumor immune responses in patients with cancer. In most instances, the identity of the relevant tumor associated antigens is not known. Consequently, autologous or allogeneic tumor cells have been used as a source of antigen for vaccination. This approach has taken advantage of the recent identification of factors that regulate the priming of systemic immunity. Tumor cells genetically modified in vitro to secrete cytokines or express co-stimulatory molecules have been studied for the ability to activate systemic antitumor immunity when used as a vaccine. Such studies in animal models demonstrate that vaccination with a number of genetically modified tumor cell vaccine constructs results in protection against a subsequent systemic tumor challenge, or eradication of a small pre-established systemic tumor burden. These studies form the basis for several on going phase I clinical trials exploring this approach in patients with solid tumors. While these early studies have been promising, there is evidence to suggest that the systemic immunity primed by tumor vaccination has limited efficacy against more advanced tumor burdens. We and others have shown that with time, tolerance to tumor antigens develops, and with further tumor progression, a more global tumor-induced immunosuppression occurs. Consequently, tumor cell vaccination may hold the greatest promise if preceded by a significant reduction in tumor burden. For many malignancies, autologous bone marrow transplantation offers the greatest opportunity to achieve a state of minimal residual disease. Furthermore, the reconstitution of the immune system following transplantation may restore the capacity to respond to tumor associated antigens to which tolerance had been established. The major focus of this project is to explore the integration of tumor-specific active immunotherapy with myeloablative chemotherapy and autologous peripheral blood stem-cell (PBSC) transplantation. This strategy will be studied in an animal model of B cell lymphoma, as well as in patients with indolent lymphoma and multiple myeloma. Targeting these initial studies to the therapy of two B-cell lineage malignancies will enable an analysis of immunity raised to a defined tumor-specific antigen, i.e. immunoglobulin idiotype protein. in this way, we seek to address unambiguously the ability to generate tumor specific immunity in the transplant setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA015396-26S1
Application #
6344687
Study Section
Project Start
1999-07-27
Project End
2000-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2000
Total Cost
$225,914
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; BolaƱos-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications